What the evidence describes
Seventy-five people with subjective cognitive impairment were randomized to 600 or 1,200 milligrams of Tremella fuciformis daily or placebo. The placebo arm contained 15 participants, versus 30 in each active arm. [1]
The active groups improved more on memory-complaint scores and selected short-term memory and executive-function measures. Brain-imaging analyses were exploratory, and reported adverse-event frequency did not differ significantly. [1]
What the finding means
Short follow-up and a small comparator group limit confidence and safety inference. The results do not establish prevention of dementia or equivalence to a skincare product, soup or another extract. Funding and conflicts were not established from the abstract. [1]
A hypothetical distinction
Imagine a questionnaire improves over eight weeks. That is not an observation of dementia incidence over years.
| Detail | Interpretation |
|---|---|
| Finding | Preserve the measured or observed outcome |
| Context | Species, preparation or setting matters |
| Limit | No universal safety or benefit guarantee |
Sources for this article
- Efficacy and Safety of Tremella fuciformis in Individuals with Subjective Cognitive Impairment: A Randomized Controlled Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.